Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus bermosudil-like antibody first-line treatment for advanced pheochromocytoma/paraganglioma
ChiCTR2500102436Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and bermekimab in pheochromocytoma and Paraganglioma (PGL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
anlotinibbermekimab
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on ChiCTR2500102436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102436.